Published in Lancet on July 15, 2010
The science and practice of HIV prevention. Lancet (2010) 1.49
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med (2007) 6.30
Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA (2008) 6.07
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ (2009) 4.19
Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS (2007) 3.70
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr (2007) 3.38
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS (2010) 2.98
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol (2009) 2.51
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med (2008) 2.43
Physical inactivity, excess adiposity and premature mortality. Obes Rev (2003) 2.32
Mortality and educational level among diabetic and non-diabetic population in the Turin Longitudinal Study: a 9-year follow-up. Int J Epidemiol (2004) 2.26
Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS (2010) 2.04
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med (2011) 4.21
Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS (2010) 3.93
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med (2004) 2.92
Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr (2007) 2.91
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis (2014) 2.65
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.37
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17
Use of a serum beta-glucan assay for diagnosis of HIV-related Pneumocystis jiroveci pneumonia in patients with negative microscopic examination results. Clin Infect Dis (2008) 2.10
Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy. JAMA Intern Med (2013) 2.10
Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis (2006) 2.01
Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis (2003) 1.89
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med (2014) 1.75
Cost-effectiveness of genotype testing for primary resistance in Brazil. J Acquir Immune Defic Syndr (2015) 1.73
Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr (2010) 1.70
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr (2013) 1.68
Editorial commentary: can we break the habit of routine CD4 monitoring in HIV care? Clin Infect Dis (2013) 1.66
Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis (2003) 1.62
The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS (2008) 1.59
Renal safety of tenofovir disoproxil fumarate. AIDS Read (2007) 1.58
Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin Infect Dis (2004) 1.57
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis (2007) 1.57
Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med (2005) 1.56
Retroviral rebound syndrome with fatal outcome after discontinuation of antiretroviral therapy. Clin Infect Dis (2005) 1.45
Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis (2006) 1.43
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis (2011) 1.40
Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases. AIDS Read (2008) 1.40
Predicting virologic failure in an HIV clinic. Clin Infect Dis (2010) 1.39
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS (2012) 1.34
Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. AIDS (2013) 1.23
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr (2014) 1.22
Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One (2010) 1.21
Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med (2002) 1.21
HIV and syphilis coinfection: trends and interactions. AIDS Clin Care (2003) 1.15
Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis (2005) 1.14
Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr (2002) 1.13
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis (2002) 1.07
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr (2016) 1.07
Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr (2014) 1.06
Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview. Clin Infect Dis (2004) 1.03
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis (2012) 0.99
Metabolic and cardiovascular complications in HIV-infected patients: new challenges for a new age. J Infect Dis (2012) 0.98
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. J Infect Dis (2012) 0.96
When to start antiretroviral therapy--ready when you are? N Engl J Med (2009) 0.93
Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. J Int Assoc Physicians AIDS Care (Chic) (2004) 0.91
Male sexual dysfunction associated with antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 0.91
Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen. J Acquir Immune Defic Syndr (2003) 0.89
Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antivir Ther (2012) 0.88
Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS (2014) 0.86
Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS (2013) 0.85
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr (2014) 0.84
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development. HIV Clin Trials (2012) 0.84
FDA approval: maraviroc. AIDS Clin Care (2007) 0.84
Beta-glucan for Pneumocystis pneumonia diagnosis in persons with AIDS: authors' reply. AIDS (2013) 0.83
Updated DHHS treatment guidelines. AIDS Clin Care (2006) 0.83
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. J Infect Dis (2012) 0.83
Assessing risk for cardiovascular disease in patients with human immunodeficiency virus: Why it matters. Circulation (2010) 0.81
Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection. AIDS (2003) 0.81
HSV-1 encephalitis complicated by cerebral hemorrhage in an HIV-positive person. AIDS Read (2009) 0.80
Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One (2010) 0.79
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. J Antimicrob Chemother (2014) 0.79
Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s. J Acquir Immune Defic Syndr (2015) 0.79
FDA approval: darunavir. AIDS Clin Care (2006) 0.77
A Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil fumarate (TDF), Each Coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. J Acquir Immune Defic Syndr (2017) 0.76
Removing legal barriers to high-quality care for HIV-infected patients. N Engl J Med (2012) 0.76
Antiretroviral therapy for treatment-naïve patients: a review of recent literature and the updated guidelines. Curr Infect Dis Rep (2009) 0.76
Top stories of 2004. Back to the future: lopinavir/ritonavir as "monotherapy". AIDS Clin Care (2005) 0.76
Report from the 13th retrovirus conference. Vicriviroc less effective than efavirenz in treatment-naive patients. AIDS Clin Care (2006) 0.75
Projected survival gains from revising state laws requiring written opt-in consent for HIV testing. J Gen Intern Med (2011) 0.75
Current state and limitations of daily oral therapy for treatment. Curr Opin HIV AIDS (2015) 0.75
Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. HIV Clin Trials (2015) 0.75
Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion. AIDS (2014) 0.75
Maraviroc for treatment-naive patients with HIV-1 infection: is the glass half empty or half full? J Infect Dis (2010) 0.75
Antiretroviral therapy: now "it just works". Clin Infect Dis (2011) 0.75
Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents. HIV Clin Trials (2009) 0.75
Tenofovir/FTC approved for PrEP...but issues remain regarding implementation. J Watch AIDS Clin Care (2012) 0.75
Meeting notes from ICAAC. D-D4FC (Reverset): further data on treatment-experienced patients. AIDS Clin Care (2005) 0.75
Meeting notes from ICAAC. NRTI-only regimens: making a comeback? AIDS Clin Care (2005) 0.75
Report from the 12th Retrovirus Conference. Resistance. AIDS Clin Care (2005) 0.75
Getting started with your HIV care. Posit Aware (2014) 0.75
New HCV treatments look promising for HIV/HCV-coinfected patients. J Watch AIDS Clin Care (2012) 0.75
Special feature. Year in review 2011. J Watch AIDS Clin Care (2012) 0.75
Meeting report from the XV International AIDS Conference. Structured treatment interruption and other novel treatment strategies. AIDS Clin Care (2004) 0.75
Meeting notes from ICAAC. Choosing the right HCV-coinfected patients to treat. AIDS Clin Care (2005) 0.75
Revised guidelines for the treatment of OIs. AIDS Clin Care (2005) 0.75
Antiretroviral rounds. The ABCs of LGV. AIDS Clin Care (2005) 0.75
FDA approval: tipranavir. AIDS Clin Care (2005) 0.75
Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid. AIDS Clin Care (2005) 0.75
Report from the 12th Retrovirus Conference. New drugs. AIDS Clin Care (2005) 0.75
Meeting notes from the 3rd IAS Conference. Advances in the treatment of hepatitis/HIV coinfection. AIDS Clin Care (2005) 0.75
Antiretroviral rounds. Suppressed but with side effects--now what? J Watch AIDS Clin Care (2010) 0.75